Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.

ABSTRACT:

Background

There is a lack of biomarkers to predict outcome with targeted therapy in metastatic clear cell renal cancer (mccRCC). This may be because dynamic molecular changes occur with therapy.

Objective

To explore if dynamic, targeted-therapy-driven molecular changes correlate with mccRCC outcome.

Design, setting, and participants

Multiple frozen samples from primary tumours were taken from sunitinib-naïve (n=22) and sunitinib-treated mccRCC patients (n=23) for protein analysis. A cohort (n=86) of paired, untreated and sunitinib/pazopanib-treated mccRCC samples was used for validation. Array comparative genomic hybridisation (CGH) analysis and RNA interference (RNAi) was used to support the findings.

Intervention

Three cycles of sunitinib 50mg (4 wk on, 2 wk

SUBMITTER: Stewart GD 

PROVIDER: S-EPMC4410300 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature